Article Information
History
- September 18, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- 1Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
- 2Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
- 3Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
- 4MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom
- 5Department of Epidemiology and Biostatistics, School of Public Health, St Mary’s Hospital, Imperial College London, London, United Kingdom
- 6Clinical Pharmacology and Therapeutics Section, Institute of Medical and Biomedical Education and Institute for Infection and Immunity, St George’s, University of London, London, United Kingdom
- 7Clinical Pharmacology Group, Pharmacy and Medicines Directorate, St George’s University Hospitals NHS Foundation Trust, London, United Kingdom
- 8Novo Nordisk Research Centre Oxford, Old Road Campus, Oxford, United Kingdom
- ↵*Corresponding author:
Susanna C. Larsson, PhD Unit of Cardiovascular and Nutritional Epidemiology Institute of Environmental Medicine Karolinska Institutet, 17177 Stockholm, Sweden Tel: +46-8-52486059; Email: susanna.larsson{at}ki.se
Posted September 18, 2020.
Genetically proxied inhibition of interleukin-6 signaling: opposing associations with susceptibility to COVID-19 and pneumonia
